110 related articles for article (PubMed ID: 21740078)
1. Fimasartan.
Am J Cardiovasc Drugs; 2011 Aug; 11(4):249-52. PubMed ID: 21740078
[TBL] [Abstract][Full Text] [Related]
2. Fimasartan, a novel angiotensin II receptor antagonist.
Kim JH; Lee JH; Paik SH; Kim JH; Chi YH
Arch Pharm Res; 2012 Jul; 35(7):1123-6. PubMed ID: 22864732
[TBL] [Abstract][Full Text] [Related]
3. [Angiotensin receptor antagonists. A new class of antihypertensive agents].
Mann J
Dtsch Med Wochenschr; 1996 Apr; 121(17):568-71. PubMed ID: 8620827
[No Abstract] [Full Text] [Related]
4. PK/PD evaluation of fimasartan for the treatment of hypertension Current evidences and future perspectives.
Angeli F; Verdecchia P; Trapasso M; Pane M; Signorotti S; Reboldi G
Expert Opin Drug Metab Toxicol; 2018 May; 14(5):533-541. PubMed ID: 29676941
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of fimasartan in patients with arterial hypertension (Safe-KanArb study): an open-label observational study.
Park JB; Sung KC; Kang SM; Cho EJ
Am J Cardiovasc Drugs; 2013 Feb; 13(1):47-56. PubMed ID: 23344912
[TBL] [Abstract][Full Text] [Related]
6. Characterizing the time-course of antihypertensive activity and optimal dose range of fimasartan via mechanism-based population modeling.
Bulitta JB; Paik SH; Chi YH; Kim TH; Shin S; Landersdorfer CB; Jiao Y; Yadav R; Shin BS
Eur J Pharm Sci; 2017 Sep; 107():32-44. PubMed ID: 28599987
[TBL] [Abstract][Full Text] [Related]
7. Effect of age on the pharmacokinetics of fimasartan (BR-A-657).
Lee HW; Lim MS; Seong SJ; Lee J; Park J; Seo JJ; Cho JY; Yu KS; Yoon YR
Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1337-44. PubMed ID: 21950382
[TBL] [Abstract][Full Text] [Related]
8. New angiotensin-II blocker.
Lilley LL; Guanci R
Am J Nurs; 1996 Mar; 96(3):20. PubMed ID: 8607540
[No Abstract] [Full Text] [Related]
9. Angiotensin II receptor inhibition. A new therapeutic principle.
Messerli FH; Weber MA; Brunner HR
Arch Intern Med; 1996 Sep; 156(17):1957-65. PubMed ID: 8823149
[TBL] [Abstract][Full Text] [Related]
10. Fimasartan for independent reduction of blood pressure variability in mild-to-moderate hypertension.
Shin MS; Kang DR; Kim C; Cho EJ; Sung KC; Kang SM; Kim DS; Joo SJ; Lee SH; Hwang KK; Park JB
Drug Des Devel Ther; 2016; 10():1573-80. PubMed ID: 27217724
[TBL] [Abstract][Full Text] [Related]
11. [Diabetic patient with hypertension takes A-I I blocker. Less likely dialysis].
MMW Fortschr Med; 2002 Feb; 144(8):52. PubMed ID: 11910830
[No Abstract] [Full Text] [Related]
12. Clinic and Home Blood Pressure Lowering Effect of an Angiotensin Receptor Blocker, Fimasartan, in Postmenopausal Women with Hypertension.
Kim SY; Joo SJ; Shin MS; Kim C; Cho EJ; Sung KC; Kang SM; Kim DS; Lee SH; Hwang KK; Park JB
Medicine (Baltimore); 2016 May; 95(22):e3764. PubMed ID: 27258507
[TBL] [Abstract][Full Text] [Related]
13. Fimasartan: A New Angiotensin Receptor Blocker.
Lee HY; Oh BH
Drugs; 2016 Jul; 76(10):1015-22. PubMed ID: 27272555
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the drug-drug interactions between fimasartan and hydrochlorothiazide in healthy volunteers.
Jeon H; Lim KS; Shin KH; Kim J; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
J Cardiovasc Pharmacol; 2012 Jan; 59(1):84-91. PubMed ID: 21934629
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Safety of a Novel Angiotensin Receptor Blocker, Fimasartan, According to the Absence or Presence of Underlying Liver Disease in Korean Hypertensive Patients: A Prospective, 12-Month, Observational Study.
Oh GC; Joo KW; Kim MA; Choi DJ; Kim YJ; Lee HY
Drug Des Devel Ther; 2020; 14():1341-1349. PubMed ID: 32308367
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological Profiles of a Highly Potent and Long-Acting Angiotensin II Receptor Antagonist, Fimasartan, in Rats and Dogs after Oral Administration.
Paik SH; Chi YH; Lee JH; Han HS; Lee KT
Biol Pharm Bull; 2017; 40(7):992-1001. PubMed ID: 28674263
[TBL] [Abstract][Full Text] [Related]
17. Fimasartan increases glucose-stimulated insulin secretion in patients with type 2 diabetes and hypertension compared with amlodipine.
Yang YS; Lim MH; Lee SO; Roh E; Ahn CH; Kwak SH; Cho YM; Kim S; Mari A; Park KS; Jung HS
Diabetes Obes Metab; 2018 Jul; 20(7):1670-1677. PubMed ID: 29546730
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II receptors and angiotensin II receptor antagonists.
Timmermans PB; Wong PC; Chiu AT; Herblin WF; Benfield P; Carini DJ; Lee RJ; Wexler RR; Saye JA; Smith RD
Pharmacol Rev; 1993 Jun; 45(2):205-51. PubMed ID: 8372104
[No Abstract] [Full Text] [Related]
19. Angiotensin II antagonism: a new avenue of hypertension management.
Gavras H
Blood Press Suppl; 1997; 1():42-6. PubMed ID: 9285108
[TBL] [Abstract][Full Text] [Related]
20. Historical development of losartan (DuP 753) and angiotensin II receptor subtypes.
Wong PC; Timmermans PB
Blood Press Suppl; 1996; 3():11-4. PubMed ID: 8973760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
